Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
17
SYNB Quote, Financials, Valuation and Earnings
Last price:
$29.93
Seasonality move
:
3.86%
Day range:
$29.68 - $29.91
52-week range:
$28.24 - $33.23
Dividend yield:
0.72%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
205
Avg. volume:
--
1-year change:
4.62%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
$29.68 | -- | -- | -- | $0.21 | 0.72% | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
$32.31 | -- | -- | -- | $0.01 | 0.55% | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
$24.45 | -- | -- | -- | $0.00 | 0% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$22.76 | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | 1.222 | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | 1.154 | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | 0.000 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
Putnam BioRevolution ETF vs. Competitors
-
Which has Higher Returns SYNB or GDOC?
Goldman Sachs Future Health Care Equity ETF has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat Goldman Sachs Future Health Care Equity ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- -
What do Analysts Say About SYNB or GDOC?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Goldman Sachs Future Health Care Equity ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than Goldman Sachs Future Health Care Equity ETF, analysts believe Putnam BioRevolution ETF is more attractive than Goldman Sachs Future Health Care Equity ETF.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 GDOCGoldman Sachs Future Health Care Equity ETF0 0 0 -
Is SYNB or GDOC More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYNB or GDOC?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.72%. Goldman Sachs Future Health Care Equity ETF offers a yield of 0.55% to investors and pays a quarterly dividend of $0.01 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. Goldman Sachs Future Health Care Equity ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or GDOC?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than Goldman Sachs Future Health Care Equity ETF quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than Goldman Sachs Future Health Care Equity ETF's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while Goldman Sachs Future Health Care Equity ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for Goldman Sachs Future Health Care Equity ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- --
-
Which has Higher Returns SYNB or OZEM?
Roundhill GLP-1 & Weight Loss ETF has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat Roundhill GLP-1 & Weight Loss ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -
What do Analysts Say About SYNB or OZEM?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Roundhill GLP-1 & Weight Loss ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than Roundhill GLP-1 & Weight Loss ETF, analysts believe Putnam BioRevolution ETF is more attractive than Roundhill GLP-1 & Weight Loss ETF.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 -
Is SYNB or OZEM More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYNB or OZEM?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.72%. Roundhill GLP-1 & Weight Loss ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. Roundhill GLP-1 & Weight Loss ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or OZEM?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than Roundhill GLP-1 & Weight Loss ETF quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than Roundhill GLP-1 & Weight Loss ETF's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while Roundhill GLP-1 & Weight Loss ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for Roundhill GLP-1 & Weight Loss ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- --
-
Which has Higher Returns SYNB or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Putnam BioRevolution ETF's net margin of --. Putnam BioRevolution ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYNBPutnam BioRevolution ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About SYNB or THNR?
Putnam BioRevolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Putnam BioRevolution ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Putnam BioRevolution ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings SYNBPutnam BioRevolution ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is SYNB or THNR More Risky?
Putnam BioRevolution ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYNB or THNR?
Putnam BioRevolution ETF has a quarterly dividend of $0.21 per share corresponding to a yield of 0.72%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Putnam BioRevolution ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYNB or THNR?
Putnam BioRevolution ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Putnam BioRevolution ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Putnam BioRevolution ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Putnam BioRevolution ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYNBPutnam BioRevolution ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 6.9% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.97% over the past day.
